Afatinib a Better Choice for EGFR-mutated Lung Cancer in First-line Treatment

SINGAPORE and LUGANO, Switzerland, Dec. 21, 2015 /PRNewswire/ --

LUX-Lung 7 trial reveals that the second-generation EGFR tyrosine kinase inhibitor significantly improved PFS in naive patients with advanced mutated lung cancer compared to gefitinib 

TRADITIONAL CHINESE FULL TEXT 
http://www.esmo.org/content/download/73092/1302111/TRAD+CHIN_PR_LBA2_Lung_LUXLung7.pdf

SIMPLE CHINESE FULL TEXT
http://www.esmo.org/content/download/73091/1302105/SIMP+CHIN_PR_LBA2_Lung_LUXLung7.pdf

JAPANESE FULL TEXT 
http://www.esmo.org/content/download/73090/1302099/JAP_PR_LBA2_Lung_LUXLung7.pdf

Patients with EGFR-activating mutations in advanced lung cancer seem to benefit more from afatinib than gefitinib as first-line treatment, researchers report at the first ESMO Asia 2015 Congress in Singapore.

In the global, randomised, open-label Phase IIb LUX-Lung 7 (LL7) trial ^[1], the irreversible ErbB family blocker afatinib significantly improved efficacy versus gefitinib across a range of clinically relevant endpoints, such as progression-free survival, time-to-treatment failure and objective response rate. "Based on these results I would consider afatinib as the EGFR tyrosine kinase inhibitor (TKI) of choice for the first-line treatment for patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC)," lead author, Professor Keunchil Park, head of the Division of Hematology/Oncology at Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, said.

NSCLC is the most common type of lung cancer: activating epidermal growth factor receptor (EGFR) gene mutations are more frequently observed in non-smokers and women, and occur in 50% of Asians and only 10% of non-Asians.

In the first head-to-head LUX-Lung 7 trial, afatinib candidates to be a better choice for EGFR-mutation positive NSCLC naive patients who had received no prior treatment. "First-line afatinib treatment significantly reduced the risk of lung cancer progression by 27% versus gefitinib," Park said. "Interestingly, the improvement in progression-free survival became more pronounced over time with a significantly higher proportion of patients alive and progression-free at 18 months (27% vs 15%; p=0.018) and 24 months (18% vs 8%; p=0.018), showing a greater long-term benefit of using the irreversible ErbB family blocker afatinib."

For media RSVPs or enquiries, please contact: 

Ruder Finn Asia
Petrina Loh
Account Executive
DID: +65-6336-7694 / Mobile: +65-9005-2790
lohp@ruderfinnasia.com 

Ruder Finn Asia
Michelle Tan
Account Executive
DID: +65-6336-6408 / Mobile: +65-9186-4848
tanm@ruderfinnasia.com

ESMO Press Office   media@esmo.org

About PR Newswire PR Newswire is the premier global provider of news release distribution and multimedia platforms that enable marketers, public relations officers and investor relations professionals to engage with their key audiences: businesses and consumers, the media, and investors.